Back to News
Market Impact: 0.3
Johnson & Johnson Reports Durable Five-Year Remissions With CARVYKTI In Myeloma
Source: Nasdaq
Healthcare & BiotechProduct Launches
Johnson & Johnson reported new long-term Phase 2 CARTITUDE-2 data indicating durable treatment-free remissions following a single infusion of CARVYKTI (ciltacabtagene autoleucel) in multiple myeloma patients. The update supports the clinical profile of J&J's CAR-T therapy and its broader multiple-myeloma portfolio, although the article excerpt does not provide specific efficacy or safety figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
JNJ0.72
More News
- Johnson & Johnson says Tremfya eases spinal pain in Phase 4 psoriatic arthritis study
- Anthropic Goes Big on Compute, Microsoft Rethinks AI
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Details on U.S.-China trade negotiations coming Monday, USTR Greer says
- Meta's 'powerful breakout' sets up a unique trading strategy, says Mike Khouw